Previous 10 | Next 10 |
SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Mee...
Opiant Pharmaceuticals, Inc. (OPNT) Q1 2022 Results Conference Call May 10, 2022 04:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor Relations Dr. Roger Crystal - Chief Executive Officer Dr. Phil Skolnick - Chief Scientific Officer David O'Toole - Chief F...
Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. ...
Gainers: Trecora Resources (TREC) +27%. Golden Matrix Group (GMGI) +24%. Charge Enterprises (CRGE) +21%. Inspired Entertainment (INSE) +20%. Celsius Holdings (CELH) +20%. QualTek Services (QTEK) +18%. Blue Water Vaccines (BWV) +18%. Grocery Outlet Holding (GO) +17%. H&R Block (HRB) +17%. ...
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q1 GAAP EPS of -$2.43 misses by $1.68. Revenue of $4.47M (-30.0% Y/Y) misses by $1.43M. For further details see: Opiant Pharmaceuticals GAAP EPS of -$2.43 misses by $1.68, revenue of $4.47M misses by $1.43M
SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March ...
SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended Marc...
Gainers: GTY Technology Holdings (GTYH) +114%. Vaxxinity (VAXX) +57%. Zymeworks (ZYME) +35%. Redbox Entertainment (RDBX) +33%. Finch Therapeutics Group (FNCH) +29%. Opiant Pharmaceuticals (OPNT) +29%. Puyi (PUYI) +27%. Cyngn (CYN) +24%. Clearwater (CLW) +24%. Anixa Biosciences (ANIX) +21%. Lo...
Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release PR Newswire SANTA MONICA, Calif. , April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 202...
Update: Opiant Pharmaceuticals (NASDAQ:OPNT) has advised readers to disregard the news release issued via PR Newswire on Thursday about the purported licensing deal to market the company’s opioid overdose therapy OPNT003 in the EU and U.K. “This release contains incorrect inform...
News, Short Squeeze, Breakout and More Instantly...
Opiant Pharmaceuticals Inc. Company Name:
OPNT Stock Symbol:
NASDAQ Market:
CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant c...
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant...
FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for...